← Laboratory Corporation of America overview

Laboratory Corporation of America vs Alignment Healthcare LLC: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Laboratory Corporation of America Holdings (LH)

Q3 202622 Jun – 22 Sep 2026

▲2▼1

Labcorp launches new tests, raises guidance, but Medicare fee cut proposal weighs

New product launches and Medicare coverage Labcorp launched ColoSense, the first FDA-approved at-home RNA colorectal cancer test, gained Medicare coverage for NASHnext, and introduced the first FDA-cleared Alzheimer's blood test. These expand its testing menu and open new revenue streams.
These launches are new in Q3 and show innovation driving growth.
Strong financial performance and raised guidance Labcorp beat Q2 estimates, raised its 2026 guidance, completed a large buyback, and set long-term revenue growth targets of 5%–8%. This signals confidence in its business and returns cash to shareholders.
These are new financial updates that positively influenced investor sentiment.
Proposed Medicare lab fee cuts CMS proposed cutting Medicare lab fees by up to 15% starting January 2027, citing overpayment versus private insurers. This sharply pressured Labcorp and Quest shares, raising concerns about future margins and revenue.
This is a new regulatory threat that negatively impacted the stock.
Reaffirmed outlook despite reimbursement pressure Labcorp reaffirmed its 2026–2029 outlook, saying it already assumed reimbursement pressure. However, the stock still fell about 3% in Q3, reflecting investor caution over potential margin and revenue risks.
This shows the counterweight: management confidence versus market skepticism.

September 202628 Aug – 22 Sep 2026

▲2▼1

New Alzheimer's Test and Growth Plan Meet Medicare Fee Cut Threat

First FDA-cleared single-biomarker Alzheimer's blood test Labcorp launched the first FDA-cleared single-biomarker Alzheimer's blood test, a simple blood draw that could replace costly PET scans. It also allied with the largest US primary care network to drive routine orders, supporting future test volume and revenue.
New product and partnership that can lift future demand and revenue.
Investor Day reaffirms 2026 guidance and sets 5%-8% growth target Labcorp reaffirmed 2026 adjusted EPS guidance above Wall Street estimates and set long-term targets of 5%-8% annual revenue growth and 8.5%-11.5% EPS growth through 2029. The plan includes margin expansion and AI/robotics, giving investors a clearer growth path.
Directly supports earnings expectations and long-term valuation.
CMS proposes up to 15% cut in Medicare lab fees CMS proposed cutting Medicare lab payments by up to 15% starting January 2027, saying Medicare pays 16% more than private insurers. Labcorp and Quest shares fell sharply. If finalized, this would lower reimbursement for routine tests and pressure revenue and margins.
A major regulatory threat that directly reduces future payments.
Labcorp says CMS cuts won't change 2026-2029 outlook Labcorp reaffirmed its 2026-2029 growth targets despite the proposed Medicare cuts, saying it already accounted for continued reimbursement pressure. It warned the cuts could hurt patient access and backs the RESULTS Act. The stock still fell about 3%, showing investors remain cautious.
Company response to the cut is key to whether the negative is already priced in.

Latest28 Aug – 22 Sep 2026

▲2▼1

New Alzheimer's Test and Growth Plan Meet Medicare Fee Cut Threat

First FDA-cleared single-biomarker Alzheimer's blood test Labcorp launched the first FDA-cleared single-biomarker Alzheimer's blood test, a simple blood draw that could replace costly PET scans. It also allied with the largest US primary care network to drive routine orders, supporting future test volume and revenue.
New product and partnership that can lift future demand and revenue.
Investor Day reaffirms 2026 guidance and sets 5%-8% growth target Labcorp reaffirmed 2026 adjusted EPS guidance above Wall Street estimates and set long-term targets of 5%-8% annual revenue growth and 8.5%-11.5% EPS growth through 2029. The plan includes margin expansion and AI/robotics, giving investors a clearer growth path.
Directly supports earnings expectations and long-term valuation.
CMS proposes up to 15% cut in Medicare lab fees CMS proposed cutting Medicare lab payments by up to 15% starting January 2027, saying Medicare pays 16% more than private insurers. Labcorp and Quest shares fell sharply. If finalized, this would lower reimbursement for routine tests and pressure revenue and margins.
A major regulatory threat that directly reduces future payments.
Labcorp says CMS cuts won't change 2026-2029 outlook Labcorp reaffirmed its 2026-2029 growth targets despite the proposed Medicare cuts, saying it already accounted for continued reimbursement pressure. It warned the cuts could hurt patient access and backs the RESULTS Act. The stock still fell about 3%, showing investors remain cautious.
Company response to the cut is key to whether the negative is already priced in.

July 202622 Jun – 12 Aug 2026

▲4

Labcorp's new tests and raised guidance drive positive outlook

New at-home colorectal cancer test Labcorp launched ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare. This expands its test menu and could add recurring revenue from a large screening market.
New product launch with Medicare coverage directly supports future revenue growth.
Medicare coverage for NASHnext liver test Medicare will cover and reimburse Labcorp's NASHnext blood test for liver disease starting August 2026, at about $252 per test. This should boost test volume and create a new recurring revenue stream.
New reimbursement approval expands market access and revenue potential.
Raised profit forecast on strong testing demand Labcorp beat Q2 estimates and raised its 2026 earnings and revenue guidance, driven by steady diagnostic testing and growth in drug-development services. This signals management confidence and supports a higher stock price.
Upgraded guidance and earnings beat are key positive catalysts for the stock.
Expanded oncology testing and buyback Labcorp launched the first FDA-approved PTEN companion diagnostic for prostate cancer and completed a large share buyback. These moves strengthen its precision oncology position and return cash to shareholders, supporting the stock.
New oncology test and buyback completion reinforce growth and shareholder value.

22 Jun – 12 Aug 2026

▲4

Labcorp's new tests and raised guidance drive positive outlook

New at-home colorectal cancer test Labcorp launched ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare. This expands its test menu and could add recurring revenue from a large screening market.
New product launch with Medicare coverage directly supports future revenue growth.
Medicare coverage for NASHnext liver test Medicare will cover and reimburse Labcorp's NASHnext blood test for liver disease starting August 2026, at about $252 per test. This should boost test volume and create a new recurring revenue stream.
New reimbursement approval expands market access and revenue potential.
Raised profit forecast on strong testing demand Labcorp beat Q2 estimates and raised its 2026 earnings and revenue guidance, driven by steady diagnostic testing and growth in drug-development services. This signals management confidence and supports a higher stock price.
Upgraded guidance and earnings beat are key positive catalysts for the stock.
Expanded oncology testing and buyback Labcorp launched the first FDA-approved PTEN companion diagnostic for prostate cancer and completed a large share buyback. These moves strengthen its precision oncology position and return cash to shareholders, supporting the stock.
New oncology test and buyback completion reinforce growth and shareholder value.

Alignment Healthcare LLC (ALHC)

Q3 20262 Jul – 8 Oct 2026

▼3▲1

ALHC: Strong H1 Growth Undone by Legal, Regulatory, and Ratings Setbacks

Strong H1 2026 Results and Raised Guidance Alignment Healthcare reported robust first-half 2026 results, with Q1 revenue up 33.3% to $1.24B and Q2 up 31.6% to $1.34B, beating estimates. Membership grew ~31.5% and adjusted EBITDA rose 60%, prompting raised full-year guidance.
This positive operational performance was a key driver of investor sentiment during the period.
Whistleblower Lawsuit and Accounting Concerns A former executive's whistleblower lawsuit alleges misclassified expenses and accounting irregularities, triggering securities investigations and a 16.7% stock drop. Potential restatements could erode trust and lead to further volatility.
This legal and accounting issue directly caused a sharp stock decline and raised serious governance concerns.
Medicare Advantage Prior-Authorization Bill Threat A bipartisan Medicare Advantage prior-authorization bill threatens higher medical loss ratios and compliance costs, causing shares to fall 12.6%. If passed, it could pressure margins and require operational changes.
This regulatory risk weighed on the stock and could impact future profitability.
CMS Star Rating Downgrade for Largest Contract CMS downgraded Alignment's largest California contract to 3.5 stars, covering ~81% of members, cutting bonus payments from 2028 and sending shares down over 20%. This also means Q3 EBITDA will dip to $20–30M due to heavy H2 spending.
The rating downgrade directly reduces future revenue and triggered a major stock sell-off.

September 20265 Aug – 8 Oct 2026

▼3▲1

ALHC hit by whistleblower probe, star downgrade; guidance raised

Whistleblower accounting probe A former executive's whistleblower complaint alleges accounting irregularities and misclassified expenses, prompting a securities law investigation. The stock fell 16.7% on the news. If true, it could force financial restatements and erode investor trust, weighing on the shares.
This is a new, serious regulatory and credibility risk that directly pressures ALHC's stock.
Raised 2026 outlook on strong first half Alignment raised full-year 2026 guidance after membership jumped 31.5% and first-half adjusted EBITDA rose 60%. But management plans heavy second-half spending, so third-quarter EBITDA is projected at just $20–30 million versus $68.1 million in Q2. The growth is real but near-term profit will dip.
It shows the underlying business is growing and management is confident, a positive counterweight to the bad news.
Medicare Advantage prior authorization bill A bipartisan bill would force MA plans to honor prior authorizations and ban retroactive payment clawbacks. If passed, it would raise medical loss ratios and compliance costs for insurers like Alignment. The stock fell 12.6% on the news.
This is a new regulatory threat that could squeeze ALHC's margins and profitability.
Medicare star rating downgrade CMS downgraded Alignment's largest California contract to 3.5 stars from 4, covering about 81% of its members. That cuts quality bonus payments starting in 2028, hitting future revenue. The stock fell over 20% on the day, a major blow to earnings outlook.
This is the most severe new negative event, directly reducing future federal funding and investor confidence.

Latest5 Aug – 8 Oct 2026

▼3▲1

ALHC hit by whistleblower probe, star downgrade; guidance raised

Whistleblower accounting probe A former executive's whistleblower complaint alleges accounting irregularities and misclassified expenses, prompting a securities law investigation. The stock fell 16.7% on the news. If true, it could force financial restatements and erode investor trust, weighing on the shares.
This is a new, serious regulatory and credibility risk that directly pressures ALHC's stock.
Raised 2026 outlook on strong first half Alignment raised full-year 2026 guidance after membership jumped 31.5% and first-half adjusted EBITDA rose 60%. But management plans heavy second-half spending, so third-quarter EBITDA is projected at just $20–30 million versus $68.1 million in Q2. The growth is real but near-term profit will dip.
It shows the underlying business is growing and management is confident, a positive counterweight to the bad news.
Medicare Advantage prior authorization bill A bipartisan bill would force MA plans to honor prior authorizations and ban retroactive payment clawbacks. If passed, it would raise medical loss ratios and compliance costs for insurers like Alignment. The stock fell 12.6% on the news.
This is a new regulatory threat that could squeeze ALHC's margins and profitability.
Medicare star rating downgrade CMS downgraded Alignment's largest California contract to 3.5 stars from 4, covering about 81% of its members. That cuts quality bonus payments starting in 2028, hitting future revenue. The stock fell over 20% on the day, a major blow to earnings outlook.
This is the most severe new negative event, directly reducing future federal funding and investor confidence.

July 20262 Jul – 31 Jul 2026

▲2▼1

Whistleblower Lawsuit and Investigations Hit ALHC Despite Strong Results

Whistleblower lawsuit and securities investigations A former executive sued on July 8, claiming Alignment misclassified expenses to inflate profits and pay. The stock fell 16.7%, and multiple law firms launched investigations, raising legal costs and uncertainty.
This is the main new negative event that drove the stock down in July.
Strong Q1 and Q2 revenue growth Alignment reported Q1 revenue up 33.3% to $1.24 billion and Q2 revenue up 31.6% to $1.34 billion, both beating estimates. Membership grew to 294,100, and the medical benefits ratio improved.
These results show underlying business strength that supports the stock despite legal issues.
Higher 2026 Star Ratings Improved Star Ratings for 2026 could lead to higher future reimbursement from Medicare, boosting revenue and profitability. This is a positive fundamental development for the company.
Star Ratings are a key driver of future Medicare payments and thus a positive catalyst.

27 Jul – 31 Jul 2026

▲1▼1

Legal Cloud Grows as Strong Q2 Earnings Beat Estimates

More law firms join accounting investigation Kaplan Fox, Holzer & Holzer, Hagens Berman, Lowey Dannenberg, and Frank R. Cruz all launched or continued investigations into Alignment's accounting. This keeps the whistleblower scandal alive, raising legal costs and uncertainty that weigh on the stock.
This is the main new negative force this period, extending the legal overhang from earlier reports.
Q2 revenue and profit beat expectations Alignment reported Q2 revenue of $1.34 billion, up 31.6%, and earnings per share of $0.17, both above analyst estimates. Membership grew to 294,100, and the medical benefits ratio improved, showing the core business is strong.
This is the only new positive fundamental news this period, providing a counterweight to the legal issues.

2 Jul – 21 Jul 2026

▼2▲1

Whistleblower Accounting Claims Trigger Investigations, Stock Plunge

Strong Q1 Earnings and Membership Growth Alignment Healthcare reported Q1 revenue of $1.24 billion, up 33.3% year-over-year, with earnings per share beating expectations. Membership grew by 48,500 to 284,800, and analysts raised full-year earnings estimates. Higher Star Ratings across all plans for 2026 could boost future reimbursement. This positive news initially pushed the stock up 10.7%.
This is a key positive driver that contrasts with the negative news later in the period, providing a balanced view.
Whistleblower Lawsuit Alleges Financial Manipulation On July 8, a former executive filed a whistleblower lawsuit alleging Alignment misclassified operating expenses as capital expenditures to inflate adjusted EBITDA and boost stock price and executive pay. The company denies the claims and vows to defend itself. The stock fell 16.7% on the news, its worst drop since February 2024.
This is the primary negative event that caused a sharp stock decline and triggered multiple investigations.
Multiple Law Firms Launch Investigations Following the whistleblower lawsuit, law firms Block & Leviton, Hagens Berman, Kaplan Fox, and Bragar Eagel & Squire announced investigations into Alignment for potential securities law violations. These investigations could lead to lawsuits and further pressure the stock as legal costs and uncertainty rise.
These investigations amplify the negative impact and keep the issue in the spotlight, affecting investor sentiment.